Skip to main content
Erschienen in: Heart and Vessels 1/2014

01.01.2014 | Original Article

Clinical significance of heart rate during acute decompensated heart failure to predict left ventricular reverse remodeling and prognosis in response to therapies in nonischemic dilated cardiomyopathy

verfasst von: Shunsuke Ishii, Takayuki Inomata, Yuki Ikeda, Takeru Nabeta, Miwa Iwamoto, Ichiro Watanabe, Takashi Naruke, Hisahito Shinagawa, Toshimi Koitabashi, Mototsugu Nishii, Ichiro Takeuchi, Tohru Izumi

Erschienen in: Heart and Vessels | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Although an increased heart rate (HR) is a strong predictor of poor prognosis in cases of chronic heart failure (HF), the clinical value of HR as a predictor in acute decompensated HF (ADHF) is unclear. Seventy-eight patients with nonischemic dilated cardiomyopathy (NIDCM) with sinus rhythm who were first hospitalized for ADHF from 2002 to 2010 were retrospectively investigated after exclusion of patients with tachycardia-induced cardiomyopathy. The patients were divided into two groups stratified by HR on admission with a median value of 113 beats/min (Group H with HR ≥ 113 beats/min; Group L with HR < 113 beats/min). Despite similar backgrounds, including pharmacotherapy for HF, HR changes responding to titration of β-blocker (BB) therapy and myocardial interstitial fibrosis, left ventricular (LV) ejection fractions improved more significantly 1 year later in Group H than in Group L (57 % ± 11 % vs. 46 % ± 12 %, P < 0.001). Cardiac event-free survival rates were also significantly improved in Group H (P = 0.038). Multiple regression analysis revealed that only the peak HR on admission was an independent predictor of LV reverse remodeling (LVRR) 1 year later (β = 0.396, P = 0.005). High HR on first admission for ADHF is a strong predictor of LVRR, with a better prognosis in the event of NIDCM in response to optimal pharmacotherapy, independent of pre-existing myocardial damage and subsequent HR reduction by BB therapy.
Literatur
1.
Zurück zum Zitat Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA (1987) Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 113:1489–1494PubMedCrossRef Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA (1987) Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 113:1489–1494PubMedCrossRef
2.
Zurück zum Zitat Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR (1992) Altered myocardial force–frequency relation in human heart failure. Circulation 85:1743–1750PubMedCrossRef Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR (1992) Altered myocardial force–frequency relation in human heart failure. Circulation 85:1743–1750PubMedCrossRef
3.
Zurück zum Zitat Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK (1991) Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 338:973–976PubMedCrossRef Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK (1991) Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 338:973–976PubMedCrossRef
4.
Zurück zum Zitat Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, Renet S, Lerebours G, Mahlberg-Gaudin F, Thuillez C (2004) Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109:1674–1679PubMedCrossRef Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, Renet S, Lerebours G, Mahlberg-Gaudin F, Thuillez C (2004) Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109:1674–1679PubMedCrossRef
5.
Zurück zum Zitat Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A (2004) Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 308:236–240PubMedCrossRef Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A (2004) Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 308:236–240PubMedCrossRef
6.
Zurück zum Zitat Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886–894PubMedCrossRef Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886–894PubMedCrossRef
7.
Zurück zum Zitat Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB (2008) Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). J Am Coll Cardiol 52:347–356PubMedCrossRef Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB (2008) Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). J Am Coll Cardiol 52:347–356PubMedCrossRef
8.
Zurück zum Zitat Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1349–1539CrossRef Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1349–1539CrossRef
9.
Zurück zum Zitat Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, Hosoda S (2004) Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324–330PubMedCrossRef Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, Hosoda S (2004) Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324–330PubMedCrossRef
10.
Zurück zum Zitat McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441–1446PubMedCrossRef McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441–1446PubMedCrossRef
11.
Zurück zum Zitat Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr, American College of Cardiology/American Heart Association (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38:2101–2113 Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr, American College of Cardiology/American Heart Association (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38:2101–2113
12.
Zurück zum Zitat Düngen HD, Apostolović S, Inkrot S, Tahirović E, Krackhardt F, Pavlović M, Putniković B, Lainscak M, Gelbrich G, Edelmann F, Wachter R, Eschenhagen T, Waagstein F, Follath F, Rauchhaus M, Haverkamp W, Osterziel KJ, Dietz R (2008) Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol 97:578–586PubMedCrossRef Düngen HD, Apostolović S, Inkrot S, Tahirović E, Krackhardt F, Pavlović M, Putniković B, Lainscak M, Gelbrich G, Edelmann F, Wachter R, Eschenhagen T, Waagstein F, Follath F, Rauchhaus M, Haverkamp W, Osterziel KJ, Dietz R (2008) Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol 97:578–586PubMedCrossRef
13.
Zurück zum Zitat Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, Nakayama M, Shimokawa H (2011) Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. Comparison between preserved and reduced ejection fraction heart failure. Circ J 75:2605–2613PubMedCrossRef Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, Nakayama M, Shimokawa H (2011) Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. Comparison between preserved and reduced ejection fraction heart failure. Circ J 75:2605–2613PubMedCrossRef
14.
Zurück zum Zitat Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ (2005) Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293:572–580PubMedCrossRef Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ (2005) Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293:572–580PubMedCrossRef
15.
Zurück zum Zitat Aronson D, Mittleman MA, Burger AJ (2004) Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 116:466–473PubMedCrossRef Aronson D, Mittleman MA, Burger AJ (2004) Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 116:466–473PubMedCrossRef
16.
Zurück zum Zitat Flannery G, Gehrig-Mills R, Billah B, Krum H (2008) Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 101:865–869PubMedCrossRef Flannery G, Gehrig-Mills R, Billah B, Krum H (2008) Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 101:865–869PubMedCrossRef
17.
Zurück zum Zitat Kim BH, Cho KI, Kim SM, Kim N, Han J, Kim JY, Kim IJ (2012) Heart rate reduction with ivabradine prevents thyroid hormone-induced cardiac remodeling in rat. Heart Vessels. doi: 10.1007/s00380-012-0304-z Kim BH, Cho KI, Kim SM, Kim N, Han J, Kim JY, Kim IJ (2012) Heart rate reduction with ivabradine prevents thyroid hormone-induced cardiac remodeling in rat. Heart Vessels. doi: 10.​1007/​s00380-012-0304-z
18.
Zurück zum Zitat The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302CrossRef The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302CrossRef
19.
Zurück zum Zitat Matsumori A (2003) Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 5:669–677PubMedCrossRef Matsumori A (2003) Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 5:669–677PubMedCrossRef
20.
Zurück zum Zitat Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717PubMedCrossRef Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717PubMedCrossRef
21.
Zurück zum Zitat Camm AJ, Fei L (1996) Chronotropic incompetence, Part II: clinical implications. Clin Cardiol 19:503–508PubMedCrossRef Camm AJ, Fei L (1996) Chronotropic incompetence, Part II: clinical implications. Clin Cardiol 19:503–508PubMedCrossRef
22.
Zurück zum Zitat Lauer MS, Okin PM, Larson MG, Evans JC, Levy D (1996) Impaired heart rate response to graded exercise: prognostic implications of chronotropic incompetence in the Framingham Heart study. Circulation 93:1520–1526PubMedCrossRef Lauer MS, Okin PM, Larson MG, Evans JC, Levy D (1996) Impaired heart rate response to graded exercise: prognostic implications of chronotropic incompetence in the Framingham Heart study. Circulation 93:1520–1526PubMedCrossRef
23.
Zurück zum Zitat Ellestad MH (1996) Chronotropic incompetence: the implication of heart rate response to exercise (compensatory parasympathetic hyperactivity?). Circulation 93:1485–1487PubMedCrossRef Ellestad MH (1996) Chronotropic incompetence: the implication of heart rate response to exercise (compensatory parasympathetic hyperactivity?). Circulation 93:1485–1487PubMedCrossRef
24.
Zurück zum Zitat Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH (1999) Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA 281:524–529PubMedCrossRef Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH (1999) Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA 281:524–529PubMedCrossRef
25.
Zurück zum Zitat Chen JY, Lee YL, Tsai WC, Lee CH, Chen PS, Li YH, Tsai LM, Chen JH, Lin LJ (2011) Cardiac autonomic functions derived from short-term heart rate variability recordings associated with heart rate recovery after treadmill exercise test in young individuals. Heart Vessels 26:282–288PubMedCrossRef Chen JY, Lee YL, Tsai WC, Lee CH, Chen PS, Li YH, Tsai LM, Chen JH, Lin LJ (2011) Cardiac autonomic functions derived from short-term heart rate variability recordings associated with heart rate recovery after treadmill exercise test in young individuals. Heart Vessels 26:282–288PubMedCrossRef
26.
Zurück zum Zitat Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR (1986) Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 74:1290–1302PubMedCrossRef Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR (1986) Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 74:1290–1302PubMedCrossRef
27.
Zurück zum Zitat Spyrou N, Rosen SD, Fath-Ordoubadi F, Jagathesan R, Foale R, Kooner JS, Camici PG (2002) Myocardial beta-adrenoceptor density one month after acute myocardial infarction predicts left ventricular volumes at six months. J Am Coll Cardiol 40:1216–1224PubMedCrossRef Spyrou N, Rosen SD, Fath-Ordoubadi F, Jagathesan R, Foale R, Kooner JS, Camici PG (2002) Myocardial beta-adrenoceptor density one month after acute myocardial infarction predicts left ventricular volumes at six months. J Am Coll Cardiol 40:1216–1224PubMedCrossRef
28.
Zurück zum Zitat Umana E, Solares CA, Alpert MA (2003) Tachycardia-induced cardiomyopathy. Am J Med 114:51–55PubMedCrossRef Umana E, Solares CA, Alpert MA (2003) Tachycardia-induced cardiomyopathy. Am J Med 114:51–55PubMedCrossRef
29.
Zurück zum Zitat Gelb BD, Garson A Jr (1990) Noninvasive discrimination of right atrial ectopic tachycardia from sinus tachycardia in “dilated cardiomyopathy”. Am Heart J 120:886–891PubMedCrossRef Gelb BD, Garson A Jr (1990) Noninvasive discrimination of right atrial ectopic tachycardia from sinus tachycardia in “dilated cardiomyopathy”. Am Heart J 120:886–891PubMedCrossRef
30.
Zurück zum Zitat Hoshikawa E, Matsumura Y, Kubo T, Okawa M, Yamasaki N, Kitaoka H, Furuno T, Takata J, Doi YL (2011) Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 107:1065–1070PubMedCrossRef Hoshikawa E, Matsumura Y, Kubo T, Okawa M, Yamasaki N, Kitaoka H, Furuno T, Takata J, Doi YL (2011) Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 107:1065–1070PubMedCrossRef
31.
Zurück zum Zitat Francis GS, Tang WH (2003) Beta-blockers and reverse remodeling: what are the implications? Am Heart J 145:200–202PubMedCrossRef Francis GS, Tang WH (2003) Beta-blockers and reverse remodeling: what are the implications? Am Heart J 145:200–202PubMedCrossRef
32.
Zurück zum Zitat Yamada T, Fukunami M, Ohmori M, Iwakura K, Kumagai K, Kondoh N, Minamino T, Tsujimura E, Nagareda T, Kotoh K, Hoki N (1993) Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint. J Am Coll Cardiol 21:628–633PubMedCrossRef Yamada T, Fukunami M, Ohmori M, Iwakura K, Kumagai K, Kondoh N, Minamino T, Tsujimura E, Nagareda T, Kotoh K, Hoki N (1993) Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint. J Am Coll Cardiol 21:628–633PubMedCrossRef
33.
Zurück zum Zitat Kawai K, Takaoka H, Hata K, Yokoya Y, Yokoyama M (1999) Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol 84:671–676PubMedCrossRef Kawai K, Takaoka H, Hata K, Yokoya Y, Yokoyama M (1999) Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol 84:671–676PubMedCrossRef
Metadaten
Titel
Clinical significance of heart rate during acute decompensated heart failure to predict left ventricular reverse remodeling and prognosis in response to therapies in nonischemic dilated cardiomyopathy
verfasst von
Shunsuke Ishii
Takayuki Inomata
Yuki Ikeda
Takeru Nabeta
Miwa Iwamoto
Ichiro Watanabe
Takashi Naruke
Hisahito Shinagawa
Toshimi Koitabashi
Mototsugu Nishii
Ichiro Takeuchi
Tohru Izumi
Publikationsdatum
01.01.2014
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 1/2014
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-013-0335-0

Weitere Artikel der Ausgabe 1/2014

Heart and Vessels 1/2014 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.